pharma · Breast Cancer · Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
Pierre Fabre Medicament
PIERRE FABRE MEDICAMENT is a pharma organization headquartered in LAVAUR, FR. Primary therapeutic focus areas include Breast Cancer, Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease, X-linked hyp
Company details
- Status
- Public
- HQ
- LAVAUR, FR
- Employees
- 176
- Programs
- 8
- Drugs
- 13
- Patents
- 0
F60087CI101
Phase 2 · other · locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)
F60087CI101 for locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs) is a Phase 2 program (other) at Pierre Fabre Medicament with 1 ClinicalTrials.gov record(s).
Internal code F60087CI101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pierre Fabre Medicament
- Phase
- Phase 2
- Modality
- other
- Indication
- locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)
- Status
- active
- Trials
- 1